‘Medically significant’ specified by the case reporter. ‘Not recovered’ and ‘Not resolved’ are the current outcomes at the time of report (14 May 2021). For simplicity of presentation, the outcome ‘Not reported’ also includes those with missing or pending outcomes. aIncludes 6 patients with compatible COVID-19 symptoms but not evaluated further given negative PCR tests.
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with Cladribine Tablets
DJ and AN are employees of Merck KGaA, Darmstadt, Germany. AG is an employee of Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany.
• Letter to the editor reporting outcomes of patients receiving Cladribine Tablets who have contracted COVID-19 and have been reported to the Merck KGaA, Darmstadt, Germany Global Patient Safety Database (data cut-off 29 June 2020)